Prenatal Diagnosis and the Spectrum of Involvement from Fragile X Mutations

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter reviews epidemiology, clinical involvement, genetic counseling, prenatal diagnostic procedures, and treatment in the fragile X spectrum disorders. The lack of fragile X mental retardation-1 protein (FMRP) leads to a seizure phenotype in the fragile X knockout (KO) mouse that improves with the use of metabotropic glutamate receptor 5 (mGluR5) antagonists as a targeted treatment for fragile X syndrome (FXS).Of the premutation-associated disorders, one can understand the most about the pathogenic mechanisms linked to FXTAS; however, similar mechanisms may be at play for both the neurodevelopmental involvement and in the early menopausal features (FXPOI). The chapter focuses on FXTAS. For X-linked disorders, including FXS, preimplantation genetic diagnosis (PGD) has been conducted successfully using multiplex nested PCR, which simultaneously tests for multiple X-linked markers. The complexity of genetic counseling has intensified with the emergence of premutation involvement in varied manifestations, including the aging problems and neurodevelopmental problems.

Original languageEnglish (US)
Title of host publicationGenetic Disorders and the Fetus: Diagnosis, Prevention and Treatment: Seventh Edition
Publisherwiley
Pages350-365
Number of pages16
ISBN (Electronic)9781118981559
ISBN (Print)9781118981528
DOIs
StatePublished - Jan 1 2016

Fingerprint

Fragile X Syndrome
Genetic Counseling
Prenatal Diagnosis
Fragile X Mental Retardation Protein
Preimplantation Diagnosis
Excitatory Amino Acid Antagonists
Mutation
Metabotropic Glutamate Receptors
Multiplex Polymerase Chain Reaction
Knockout Mice
Epidemiology
Seizures
Phenotype
Polymerase Chain Reaction

Keywords

  • Fragile X mental retardation-1 protein
  • Fragile X spectrum disorders
  • FXTAS
  • Genetic counseling
  • Preimplantation genetic diagnosis
  • Premutation-associated disorders
  • Prenatal diagnosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hagerman, R. J., & Hagerman, P. J. (2016). Prenatal Diagnosis and the Spectrum of Involvement from Fragile X Mutations. In Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment: Seventh Edition (pp. 350-365). wiley. https://doi.org/10.1002/9781118981559.ch7

Prenatal Diagnosis and the Spectrum of Involvement from Fragile X Mutations. / Hagerman, Randi J; Hagerman, Paul J.

Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment: Seventh Edition. wiley, 2016. p. 350-365.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hagerman, RJ & Hagerman, PJ 2016, Prenatal Diagnosis and the Spectrum of Involvement from Fragile X Mutations. in Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment: Seventh Edition. wiley, pp. 350-365. https://doi.org/10.1002/9781118981559.ch7
Hagerman RJ, Hagerman PJ. Prenatal Diagnosis and the Spectrum of Involvement from Fragile X Mutations. In Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment: Seventh Edition. wiley. 2016. p. 350-365 https://doi.org/10.1002/9781118981559.ch7
Hagerman, Randi J ; Hagerman, Paul J. / Prenatal Diagnosis and the Spectrum of Involvement from Fragile X Mutations. Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment: Seventh Edition. wiley, 2016. pp. 350-365
@inbook{6a2a9a656f0f44f19b9dde4460e8a36c,
title = "Prenatal Diagnosis and the Spectrum of Involvement from Fragile X Mutations",
abstract = "This chapter reviews epidemiology, clinical involvement, genetic counseling, prenatal diagnostic procedures, and treatment in the fragile X spectrum disorders. The lack of fragile X mental retardation-1 protein (FMRP) leads to a seizure phenotype in the fragile X knockout (KO) mouse that improves with the use of metabotropic glutamate receptor 5 (mGluR5) antagonists as a targeted treatment for fragile X syndrome (FXS).Of the premutation-associated disorders, one can understand the most about the pathogenic mechanisms linked to FXTAS; however, similar mechanisms may be at play for both the neurodevelopmental involvement and in the early menopausal features (FXPOI). The chapter focuses on FXTAS. For X-linked disorders, including FXS, preimplantation genetic diagnosis (PGD) has been conducted successfully using multiplex nested PCR, which simultaneously tests for multiple X-linked markers. The complexity of genetic counseling has intensified with the emergence of premutation involvement in varied manifestations, including the aging problems and neurodevelopmental problems.",
keywords = "Fragile X mental retardation-1 protein, Fragile X spectrum disorders, FXTAS, Genetic counseling, Preimplantation genetic diagnosis, Premutation-associated disorders, Prenatal diagnosis",
author = "Hagerman, {Randi J} and Hagerman, {Paul J}",
year = "2016",
month = "1",
day = "1",
doi = "10.1002/9781118981559.ch7",
language = "English (US)",
isbn = "9781118981528",
pages = "350--365",
booktitle = "Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment: Seventh Edition",
publisher = "wiley",

}

TY - CHAP

T1 - Prenatal Diagnosis and the Spectrum of Involvement from Fragile X Mutations

AU - Hagerman, Randi J

AU - Hagerman, Paul J

PY - 2016/1/1

Y1 - 2016/1/1

N2 - This chapter reviews epidemiology, clinical involvement, genetic counseling, prenatal diagnostic procedures, and treatment in the fragile X spectrum disorders. The lack of fragile X mental retardation-1 protein (FMRP) leads to a seizure phenotype in the fragile X knockout (KO) mouse that improves with the use of metabotropic glutamate receptor 5 (mGluR5) antagonists as a targeted treatment for fragile X syndrome (FXS).Of the premutation-associated disorders, one can understand the most about the pathogenic mechanisms linked to FXTAS; however, similar mechanisms may be at play for both the neurodevelopmental involvement and in the early menopausal features (FXPOI). The chapter focuses on FXTAS. For X-linked disorders, including FXS, preimplantation genetic diagnosis (PGD) has been conducted successfully using multiplex nested PCR, which simultaneously tests for multiple X-linked markers. The complexity of genetic counseling has intensified with the emergence of premutation involvement in varied manifestations, including the aging problems and neurodevelopmental problems.

AB - This chapter reviews epidemiology, clinical involvement, genetic counseling, prenatal diagnostic procedures, and treatment in the fragile X spectrum disorders. The lack of fragile X mental retardation-1 protein (FMRP) leads to a seizure phenotype in the fragile X knockout (KO) mouse that improves with the use of metabotropic glutamate receptor 5 (mGluR5) antagonists as a targeted treatment for fragile X syndrome (FXS).Of the premutation-associated disorders, one can understand the most about the pathogenic mechanisms linked to FXTAS; however, similar mechanisms may be at play for both the neurodevelopmental involvement and in the early menopausal features (FXPOI). The chapter focuses on FXTAS. For X-linked disorders, including FXS, preimplantation genetic diagnosis (PGD) has been conducted successfully using multiplex nested PCR, which simultaneously tests for multiple X-linked markers. The complexity of genetic counseling has intensified with the emergence of premutation involvement in varied manifestations, including the aging problems and neurodevelopmental problems.

KW - Fragile X mental retardation-1 protein

KW - Fragile X spectrum disorders

KW - FXTAS

KW - Genetic counseling

KW - Preimplantation genetic diagnosis

KW - Premutation-associated disorders

KW - Prenatal diagnosis

UR - http://www.scopus.com/inward/record.url?scp=84976863960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976863960&partnerID=8YFLogxK

U2 - 10.1002/9781118981559.ch7

DO - 10.1002/9781118981559.ch7

M3 - Chapter

SN - 9781118981528

SP - 350

EP - 365

BT - Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment: Seventh Edition

PB - wiley

ER -